Mustang Bio Signs an Exclusive Worldwide Collaboration with Nationwide Children’s Hospital for Glioblastoma Multiforme

 Mustang Bio Signs an Exclusive Worldwide Collaboration with Nationwide Children’s Hospital for Glioblastoma Multiforme

Mustang Bio Signs an Exclusive Worldwide Collaboration with Nationwide Children’s Hospital for Glioblastoma Multiforme

Shots:

  • The exclusive WW collaboration agreement is to evaluate Mustang Bio’ s MB-101 (IL13Rα2-specific CAR) in combination with C134 for the treatment of glioblastoma multiforme
  • The focus of the agreement is to assess the combination, inducing anti-tumor immune response when combined with CAR-T therapy targeting solid tumors 
  • C134 is a herpes simplex virus type 1 (HSV-1) oncolytic virus, improving replication in tumors and is currently evaluated in P-I for patients with recurrent glioblastoma multiforme

Click here to read full press release/ article | Ref: Mustang Bio | Image: Ihsigns

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post